Actively Recruiting
Evaluating Safety, Pharmacokinetics, and Activity of Oral BAY 3713372 in Adults With MTAP-Deleted Solid Tumors
Led by Bayer · Updated on 2026-10-28
450
Participants Needed
63
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug BAY 3713372 to treat solid tumors that have a specific genetic deletion called MTAP deletion. This first-in-human study aims to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with these tumors. The study focuses on measuring side effects, toxicities, drug levels in the blood, and participants responses to treatment as well as how long their cancer remains stable. Participants will receive BAY 3713372 taken by mouth daily. The study has two parts a dose escalation phase where different groups receive increasing doses of the drug alone to find a safe and effective dose, followed by a dose expansion phase where more participants receive BAY 3713372 alone or combined with other treatments based on the dose found. Some groups focus on specific tumor types, including non-small cell lung cancer, pancreatic cancer, and glioblastoma. Participants will visit the study site at least twice before treatment starts and multiple times during treatment. After treatment ends, they will have follow-up visits every 9 weeks until their cancer worsens or they stop the study. Throughout the trial, health assessments include blood and urine tests, heart monitoring with electrocardiograms, scans like CT or MRI to check cancer status, and tumor sample collection. The research team will also contact participants every 3 months for up to 2 years after their last dose to monitor health and safety.
CONDITIONS
Brief Title
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Research Team
B
Bayer Clinical Trials Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here